Skip to main contentSkip to main content
You have permission to edit this article.
In honor of Independence Day, Kearney Hub is providing unlimited access to all of our content from June 28th-July 4th! Presented by Platte Valley Auto

NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine

  • 0
NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine

TUESDAY, May 10, 2022 (HealthDay News) -- The U.S. National Institutes of Health are launching an early-stage clinical trial to evaluate a potential vaccine for Epstein-Barr virus (EBV).

The study will evaluate the safety and immune response of an investigational EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant. The Laboratory of Infectious Diseases in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center developed the vaccine, while the Matrix-M adjuvant was developed by the biotechnology company Novavax.

The study plans to enroll 40 healthy adults (aged 18 to 29 years), half with evidence of prior EBV infection and half without evidence of prior EBV infection. In total, participants will receive three 50-microgram injections of the experimental vaccine in the upper arm muscle, followed by 30 to 60 minutes of observation after each dose. The second and third doses will be administered 30 days and 180 days after the initial dose. Follow-up visits will occur between each vaccination and phone calls between visits. The trial will last four years with participation lasting 18 to 30 months.

"A vaccine that could prevent or reduce the severity of infection with the EBV could reduce the incidence of infectious mononucleosis and might also reduce the incidence of EBV-associated malignancies and autoimmune diseases," Anthony S. Fauci, M.D., director of the NIAID, said in a statement.

More Information


Originally published on, part of the TownNews Content Exchange.

Build your health & fitness knowledge

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

The race to be Illinois’ next governor is also a battle among billionaires, including two whose names won’t appear on Tuesday's primary ballot. Republican candidates Darren Bailey and Richard Irvin each has a benefactor with a different vision for the party. Businessmen Ken Griffin and Richard Uihlein have combined to pour more than $60 million into the race. Griffin backs Irvin, a former prosecutor and first Black mayor of Chicago's largest suburb. Uihlein supports Bailey, a farmer and state lawmaker who fought pandemic measures such as mask mandates. Billionaire Democratic Gov. J.B. Pritzker and the Democratic Governors Association have spent millions trying to ensure Irvin isn’t the GOP nominee. Bailey is the opponent Pritzker would rather face in November.

Facebook and Instagram have begun promptly removing posts that offer abortion pills to women who may not be able to access them following a Supreme Court decision that stripped away constitutional protections for the procedure. Memes and status updates explained how women could legally get abortion pills in the mail. Some even offered to mail the prescriptions to women living in a state that has banned the procedure.  Facebook and Instagram responded by removing some of the posts. The platforms' parent company, Meta, said it has a policy against gifting or selling pharmaceutical drugs.

Leaders of Commonwealth nations are meeting in Rwanda in a summit that promises to tackle climate change, tropical diseases and other challenges deepened by the COVID-19 pandemic. The summit for Commonwealth heads of state in Kigali, the Rwandan capital, is the culmination of a series of meetings earlier in the week that have reported some success in efforts to improve the lives of people in the 54-nation bloc that is home to 2.5 billion people. More than $4 billion was pledged Thursday toward global efforts to accelerate the fight against malaria and other neglected tropical diseases.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.


Breaking News